ClinicalTrials.gg
RecruitingNCT06951217SAILUpdated Nov 5, 2026

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

A Phase 2 interventional study of AP01 in Progressive Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis (IPF), sponsored by Avalyn Pharma Inc.. Recruiting at 92 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Avalyn Pharma Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 5, 202621 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
340
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Planned enrollment
29th of 188
340 · median 61
Started
2025
with 10 others
Phase 2
82 of 236
13 open now
Primary completion
2031-12
later than 49 of 50 live
Registered
216th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 29th largest by planned enrollment of the 188 interventional ones that give a count, is one of 11 that started in 2025, is one of 82 in phase 2, reaches primary completion later than 49 of the 50 other live ones, and was the 216th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.

Read the detailed description

All participants will receive 100 mg inhaled pirfenidone inhalation solution (AP01) taken twice daily using the eFlow Nebulizer System.

The study will consist of a Screening/Baseline Visit, an open-label Treatment Period, and a Follow-up/End of Study (EOS) phone call. During the open-label Treatment Period, subjects will receive study drug (AP01 from their lead-in study). Subjects will complete an EOS follow-up phone call approximately 2 weeks after their last dose of study drug.

A paper dosing diary will be used to monitor adherence along with returns of any unused investigational product.

03

Conditions studied

  • Progressive Pulmonary Fibrosis
  • Idiopathic Pulmonary Fibrosis (IPF)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously participated in an Avalyn-sponsored inhaled antifibrotic clinical study for subjects with either idiopathic pulmonary fibrosis (IPF) (IPF subjects are excluded from the US and Canada) or progressive pulmonary fibrosis (PPF) and with the approval of the Study Physician.

Previous participation is defined as: Having completed the final visit of the Treatment Period on the full dose of study drug (either active or placebo).

  • Male subjects and female subjects of (FOCBP) agree to use highly effective measures from the time of first dose of study drug (for the male subject) or the signing of the form (ICF) (for the female subject), during the study, and until 90 days after the last dose of study drug. Subjects agree not to donate eggs or sperm during the same period.

Exclusion criteria

Exclusion Criteria:

  • Have not previously participated in an Avalyn-sponsored inhaled antifibrotic lead-in study or if the subject was permanently discontinued from the lead-in study for any reason. Subjects who discontinued study drug but continued to attend study visits are ineligible.
  • Subjects who experienced an exacerbation of asthma or of (COPD) requiring oral or systemic within 3 months of Day 1 (Screening/Baseline Visit).
  • Subjects who experienced an acute exacerbation of IPF (IPF subjects are excluded from the US and Canada) or of PPF within 3 months of Day 1 (Screening/Baseline Visit).
  • Participation in a concurrent clinical study or in a clinical study in which any other drug product aside from the Avalyn nebulized antifibrotic medication from their lead-in study was administered within the previous 30 days, or 5 half-lives of the previously administered investigational product, whichever is shorter. Subjects may be enrolled in registries.
  • History of and/or allergic reaction to pirfenidone or the to be used in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    Open-label AP01 treatment arm

    All trial participants will enroll from a Sponsor-led parent study of AP01 and receive open-label AP01 for continued evaluation of long-term safety and tolerability.

    Combination Product: AP01

Interventions

  • Combination productAP01

    AP01 will be administered open-label via the eFlow Nebulizer System

06

What researchers measure

Primary outcomes

  1. To evaluate the long-term safety and tolerability outcomes of subjects receiving Avalyn nebulized antifibrotic medications (AP01).

    The incidence of adverse events will be evaluated from the time of signing of the informed consent until approximately 2 weeks after the last dose of study drug. Examples of potential adverse events include: respiratory symptoms, liver toxicity, and skin conditions. Study participants will be monitored for adverse events via the following: vital signs (blood pressure assessed using a sphygmomanometer, temperature assessed by thermometer, pulse and respiratory rate assessed by pulse oximeter), oxygen saturation, spirometry, physical exams, blood chemistry, and quality of life assessments.

    Time frame: Through end of study; average of 6 years

Secondary outcomes

  1. To evaluate the long-term effect of Avalyn nebulized antifibrotic medications on lung function the change from baseline in forced vital capacity (FVC) will be evaluated.

    FVC will be evaluated via spirometry.

    Time frame: Through end of study; average of 6 years

  2. To evaluate the long-term effect of Avalyn nebulized antifibrotic medications on stabilization of disease.

    Stabilization of disease will be based on computational analysis of quantitative high-resolution computed tomography (HRCT) to assess the extent and pattern of interstitial lung disease present on the HRCT scans (methodologies developed by Qureight).

    Time frame: Through end of study; average of 6 years

  3. To evaluate the long-term impact of Avalyn nebulized antifibrotic medications on subject-reported quality of life (QoL).

    This outcome will evaluate the change from baseline in the 'Living with Pulmonary Fibrosis Symptoms and Impact Questionnaire' (L-PF) total score. The L-PF is a 23-point questionnaire with lower scores equating to 'less symptomatic' and higher scores equating to 'more symptomatic.'

    Time frame: Through end of study; average of 6 years

07

Study locations

88 of 92 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2031, 80 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 80 months is above that.

Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 30, 2025
StartActual
Apr 17, 2025
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 1 site removed
Show 21 added (5 United States, 5 United Kingdom, 4 Spain, 3 Australia, 1 Argentina, 1 Germany, 1 Poland, 1 Netherlands)
  • Newport Native MD, Inc. · Newport Beach, United States
  • Yale University · New Haven, United States
  • Weill Cornell · New York, United States
  • The Oregon Clinic Pulmonary East · Portland, United States
  • CIMER Centro Integral de Medicina Respiratoria · San Miguel de Tucumán, Argentina
  • Royal Prince Alfred Hospital · Camperdown, Australia
  • Wallace Street Specialist Centre/Lung Research QLD Pty Ltd · Brisbane, Australia
  • Alfred Health · Melbourne, Australia
  • Vivantes Klinikum Neukölln - Klinik für Innere Medizin - Pneumologie und Infektiologie · Berlin, Germany
  • Prywatny Gabinet Lekarski Ginekologia I Połoznictwo Ultrasonografia · Lodz, Poland
  • Hospital Universitary de Bellvitge · Barcelona, Spain
  • Hospital Universitario Marqués de Valdecilla · Santander, Spain
  • Hospital Universitario Ramon y Cajal · Madrid, Spain
  • Oxford University Hospitals NHS Foundation Trust · Oxford, United Kingdom
  • UConn Health · Farmington, United States
  • Erasmus University Medical Center · Rotterdam, Netherlands
  • Hospital Universitario Ramón y Cajal · Madrid, Spain
  • Royal Devon · Exeter, United Kingdom
  • Royal Brompton Hospital · London, United Kingdom
  • University Hospitals of North Midlands NHS Trust · Stoke-on-Trent, United Kingdom
  • St James University Hospital · Leeds, United Kingdom
Show 1 removed
  • Royal Prince Alfred Hospital · Camperdown, Australia
across 2 updates, Oct 2, 2026 – Nov 5, 2026
Site contacts
Changed at 69 sites. See the sites
Show 69 sites
  • University of Alabama at Birmingham · Birmingham, United StatesContact added t•••@cshs.org
  • University of Southern California · Los Angeles, United StatesContact added t•••@med.usc.edu
  • University of Colorado, Anschutz Medical Campus · Aurora, United StatesContact none listed→j•••@cuanschutz.edu
  • Renstar Medical Research · Ocala, United StatesContact none listed→r•••@renstar.net
  • Piedmont Healthcare, Inc. · Atlanta, United StatesContact none listed→a•••@piedmont.org
  • The University of Kansas Medical Center · Kansas City, United StatesContact none listed→m•••@kumc.eduContact person changed (no phone or email listed)
  • University of Maryland · Baltimore, United StatesContact added e•••@som.umaryland.edu
  • Johns Hopkins Asthma and Allergy Center · Baltimore, United StatesContact added m•••@jh.edu
  • Mayo Clinic Rochester · Rochester, United StatesContact none listed→l•••@mayo.edu
  • Hannibal Regional Healthcare System, Inc. · Hannibal, United StatesContact none listed→h•••@hannibalclinic.com
  • Icahn School of Medicine at Mount Sinai · New York, United StatesContact none listed→m•••@mountsinai.org
  • Columbia University · New York, United StatesContact none listed→c•••@cumc.columbia.edu
  • Piedmont HealthCare, PA · Statesville, United StatesContact none listed→j•••@piedmonthealthcare.com
  • Southeastern Research Center · Winston-Salem, United StatesContact •••0383→none listedContact none listed→j•••@southeasternresearchcenter.com
  • University of Cincinnati · Cincinnati, United StatesContact none listed→g•••@ucmail.us.edu
  • Summit Health · Bend, United StatesContact none listed→j•••@summithealth.com
  • Thomas Jefferson University · Philadelphia, United StatesContact none listed→r•••@jefferson.edu
  • Temple University Hospital · Philadelphia, United StatesContact none listed→g•••@tuhs.temple.edu
  • Lowcountry Lung and Critical Care, PA · Charleston, United StatesContact none listed→t•••@lowcountrylung.com
  • Medical University of South Carolina · Charleston, United StatesContact none listed→w•••@musc.edu
  • Vanderbilt University Medical Center · Nashville, United StatesContact none listed→j•••@vumc.org
  • El Paso Pulmonary Association, P.A. · El Paso, United StatesContact none listed→c•••@elligodirect.com
  • Baylor College of Medicine · Houston, United StatesContact •••1000→none listed
  • Intermountain Medical Center · Murray, United StatesContact none listed→p•••@imail.org
  • University of Utah · Salt Lake City, United StatesContact added m•••@hsc.utah.edu
  • Inova Healthcare · Falls Church, United StatesContact added v•••@inova.org
  • University of Washington · Seattle, United StatesContact •••4615→none listed
  • Investigaciones En Patologias Respiratorias · San Miguel de Tucumán, ArgentinaContact •••0159→none listed
  • Fundación Respirar · Buenos Aires, ArgentinaContact •••5058→none listed
  • Clinica Monte Grande · Buenos Aires, ArgentinaContact •••5094→none listed
  • …and 39 more sites
across 2 updates, Oct 2, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    7 sites added
    Show 7 added (4 United Kingdom, 1 United States, 1 Netherlands, 1 Spain)
    • UConn Health · Farmington, United States
    • Erasmus University Medical Center · Rotterdam, Netherlands
    • Hospital Universitario Ramón y Cajal · Madrid, Spain
    • Royal Devon · Exeter, United Kingdom
    • Royal Brompton Hospital · London, United Kingdom
    • University Hospitals of North Midlands NHS Trust · Stoke-on-Trent, United Kingdom
    • St James University Hospital · Leeds, United Kingdom
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Westmead Hospital · Westmead, AustraliaContact j•••@sydney.edu.au→j•••@sydney.edu.auContact person changed (no phone or email listed)
  2. Oct 2, 2026
    14 sites added, 1 site removed
    Show 14 added (4 United States, 3 Australia, 3 Spain, 1 Argentina, 1 Germany, 1 Poland, 1 United Kingdom)
    • Newport Native MD, Inc. · Newport Beach, United States
    • Yale University · New Haven, United States
    • Weill Cornell · New York, United States
    • The Oregon Clinic Pulmonary East · Portland, United States
    • CIMER Centro Integral de Medicina Respiratoria · San Miguel de Tucumán, Argentina
    • Royal Prince Alfred Hospital · Camperdown, Australia
    • Wallace Street Specialist Centre/Lung Research QLD Pty Ltd · Brisbane, Australia
    • Alfred Health · Melbourne, Australia
    • Vivantes Klinikum Neukölln - Klinik für Innere Medizin - Pneumologie und Infektiologie · Berlin, Germany
    • Prywatny Gabinet Lekarski Ginekologia I Połoznictwo Ultrasonografia · Lodz, Poland
    • Hospital Universitary de Bellvitge · Barcelona, Spain
    • Hospital Universitario Marqués de Valdecilla · Santander, Spain
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Oxford University Hospitals NHS Foundation Trust · Oxford, United Kingdom
    Show 1 removed
    • Royal Prince Alfred Hospital · Camperdown, Australia
    Site contacts Changed at 69 sites. See the sites
    Show 69 sites
    • University of Alabama at Birmingham · Birmingham, United StatesContact added t•••@cshs.org
    • University of Southern California · Los Angeles, United StatesContact added t•••@med.usc.edu
    • University of Colorado, Anschutz Medical Campus · Aurora, United StatesContact none listed→j•••@cuanschutz.edu
    • Renstar Medical Research · Ocala, United StatesContact none listed→r•••@renstar.net
    • Piedmont Healthcare, Inc. · Atlanta, United StatesContact none listed→a•••@piedmont.org
    • The University of Kansas Medical Center · Kansas City, United StatesContact none listed→m•••@kumc.eduContact person changed (no phone or email listed)
    • University of Maryland · Baltimore, United StatesContact added e•••@som.umaryland.edu
    • Johns Hopkins Asthma and Allergy Center · Baltimore, United StatesContact added m•••@jh.edu
    • Mayo Clinic Rochester · Rochester, United StatesContact none listed→l•••@mayo.edu
    • Hannibal Regional Healthcare System, Inc. · Hannibal, United StatesContact none listed→h•••@hannibalclinic.com
    • Icahn School of Medicine at Mount Sinai · New York, United StatesContact none listed→m•••@mountsinai.org
    • Columbia University · New York, United StatesContact none listed→c•••@cumc.columbia.edu
    • Piedmont HealthCare, PA · Statesville, United StatesContact none listed→j•••@piedmonthealthcare.com
    • Southeastern Research Center · Winston-Salem, United StatesContact •••0383→none listedContact none listed→j•••@southeasternresearchcenter.com
    • University of Cincinnati · Cincinnati, United StatesContact none listed→g•••@ucmail.us.edu
    • Summit Health · Bend, United StatesContact none listed→j•••@summithealth.com
    • Thomas Jefferson University · Philadelphia, United StatesContact none listed→r•••@jefferson.edu
    • Temple University Hospital · Philadelphia, United StatesContact none listed→g•••@tuhs.temple.edu
    • Lowcountry Lung and Critical Care, PA · Charleston, United StatesContact none listed→t•••@lowcountrylung.com
    • Medical University of South Carolina · Charleston, United StatesContact none listed→w•••@musc.edu
    • Vanderbilt University Medical Center · Nashville, United StatesContact none listed→j•••@vumc.org
    • El Paso Pulmonary Association, P.A. · El Paso, United StatesContact none listed→c•••@elligodirect.com
    • Baylor College of Medicine · Houston, United StatesContact •••1000→none listed
    • Intermountain Medical Center · Murray, United StatesContact none listed→p•••@imail.org
    • University of Utah · Salt Lake City, United StatesContact added m•••@hsc.utah.edu
    • Inova Healthcare · Falls Church, United StatesContact added v•••@inova.org
    • University of Washington · Seattle, United StatesContact •••4615→none listed
    • Investigaciones En Patologias Respiratorias · San Miguel de Tucumán, ArgentinaContact •••0159→none listed
    • Fundación Respirar · Buenos Aires, ArgentinaContact •••5058→none listed
    • Clinica Monte Grande · Buenos Aires, ArgentinaContact •••5094→none listed
    • …and 39 more sites

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06951217
Lead sponsor
Avalyn Pharma Inc.
Responsible party
Sponsor
First posted
Apr 30, 2025
Start date
Apr 17, 2025
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Dr. Felix Woodhead, MB BChir,PhD
Contact
fwoodhead@avalynpharma.com
+44 7999 885973
Avalyn Pharma, Inc.
study director · Avalyn Pharma Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion